810A Champion Building,301-309 Nathan Rd, Jordan Kowloon Hong Kong
hkmagicure@gmail.com
more

Doctor Introduction

Dr.Azzoli Doctor
MD

Medical School: Johns Hopkins University School of Medicine; Residency: Johns Hopkins Hospital; Fellowship: Memorial Sloan-Kettering Cancer Center;

David White Doctor
MD

Professor of clinical medicine at Harvard Medical School; Chief physician of the Division of Sleep Medicine in the Division of Laboratory Medicine at Harvard Brigham and Women's Hospital.

Jatin P. Shah Doctor
MD

The Elliott W. Strong Chair in Head and Neck Oncology at Memorial Sloan-Kettering Cancer Center in New York City.

more

Lectures

News

Evusheld (tixagevimab + cilgavi

Author: Magicure Date: 2022-11-25

Evusheld (tixagevimab + cilgavimab) is composed of two recombinant human IgG1 monoclonal antibodies tixagevimab and cilgavimab , which can mimic the bodys natural antibody defense The mechanism, by binding to different si...

  • Soliris (eculizumab)—— &quo

    Author: Magicure Date: 2022-11-21

    Soliris (eculizumab) is a complement inhibitor indicated for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Synd...

  • Significant relief from eczema

    Author: Magicure Date: 2022-11-16

    On November 15, Arcutis Biotherapeutics announced positive topline results from its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15%, a on...

  • Enhertu (DS-8201) for the treat

    Author: Magicure Date: 2022-11-15

    On November 14, Antibody drug conjugate Enhertu (DS-8201, trastuzumab deruxtecan) jointly developed and commercialized by AstraZeneca and Daiichi Sanky...

  • What is Soliris (Eculizumab) me

    Author: Magicure Date: 2022-11-08

    Soliris (Eculizumab) is a complement inhibitor . Eculizumab, the active ingredient in Soliris, is a monoclonal antibody that specifically binds to the ...

  • What is Astrazeneca Benralizuma

    Author: Magicure Date: 2022-10-09

    Benralizumab (Fasenra) is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for the add-on maintenance tre...

  • Is Lumakras (Sotorasib) FDA app

    Author: Magicure Date: 2022-09-27

    On May 28, 2021, FDA granted accelerated approval to Lumakras (Sotorasib), a RAS GTPase family inhibitor, for adult patients with KRAS G12C mutated loc...

  • HER2 positive breast cancer new

    Author: Magicure Date: 2022-09-09

    Breast cancer is caused by uncontrolled proliferation of mammary epithelial cells in response to a variety of carcinogenic factors. The symptoms of ear...

  • What is Evusheld (Tixagevimab +

    Author: Magicure Date: 2022-08-25

    AstraZenecas Evusheld (Tixagevimab + Cilgavimab) , a long-acting antibody (LAAB) combination, has received emergency use authorisation (EUA) in the US ...

About Magicure

Hong Kong Magicure Medical Center has long been focusing on the import and export of new drugs, special drugs and rare disease drugs in the field of oncology. At the same time, the medical center cooperates with a number of medical institutions in China and Hong Kong, and is committed to providing customers with efficient, convenient and safe medical services.

As an enterprise dedicated to providing safe, reliable and reassuring drugs for chronic diseases to hospitals, pharmacies and patients, Hong Kong Magicure Medical Co., Ltd. has always adhered to the business and sales tenet of honest management and attentive service and "focusing on oncology drugs and continuous improvement" The concept of "patient health", and strive to meet the medication needs of different hospitals, pharmacies and patients.